Meeting
2022 ASCO Annual Meeting
A real-world (rw) evidence study quantifying the clinical value of multi-gene testing in early-stage lung adenocarcinoma (LUAD).
Authors
Nathan A. Pennell
Cleveland Clinic, Cleveland, OH
Nathan A. Pennell , Liangliang Zhang , Katherine T Lofgren , Bharathi Muthusamy , Emily Castellanos , Karen Schwed , Olivier Humblet , Alexa Betzig Schrock , Geoffrey R. Oxnard
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8525)
DOI
10.1200/JCO.2022.40.16_suppl.8525
Abstract #
8525
Poster Bd #
152
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
FDA analysis of toxicity profiles of oral TKIs recently approved for non-small cell lung cancer based on receipt of prior immune checkpoint inhibitor therapy.
First Author: Yufan Liu
Poster
2023 ASCO Annual Meeting
Clinical outcomes among patients with advanced non-small cell lung cancer who received targeted therapy in a real-world setting.
First Author: Mo Yang
Poster
2022 ASCO Annual Meeting
Evaluation of outcomes in patients (pts) with stage 4 non-small cell lung cancer (NSCLC 4) harboring actionable oncogenic drivers (AOD) when treated prior to report of mutation without tyrosine kinase inhibitors (TKI): An Integra Connect Database (ICD) retrospective observational study.
First Author: Robert E. Smith
Poster
2022 ASCO Annual Meeting
LCMC LEADER neoadjuvant screening trial: LCMC4 evaluation of actionable drivers in early-stage lung cancers.
First Author: Boris Sepesi